FOR HEALTHCARE PROFESSIONALS ONLY

FASENRA (Benralizumab) severe Asthma Induction Dose (AID) support program (1 dose only)

This support program is meant for severe eosinophilic asthma patients. One Fasenra 30 mg dose will be provided free-of-charge (FOC) to patients based on local prescribing indication. To be eligible for this program, patients must fulfil the below medical and financial criteria as acknowledged by the prescribing physician before FOC Fasenra dose can be given to the patient. Under this program, AstraZeneca Singapore will not support any further free Fasenra stocks beyond the one FOC dose.

Indication: FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β -agonists.

Duration of Program: Till 31st Dec 2024 (inclusive)

Program Medical Criteria: Adult patients diagnosed as Severe Asthma (GINA Step 5) meeting the following criteria

1.	 History of ≥ 300 cells/µl blood eosinophils over the past 52 weeks OR ≥ 150 cells/blood eosinophils at the time of institution {if on Oral Corticosteroids (OCS)} 	
		AND
2.	2. ≥ 2 exacerbations over the past 52 weeks OR on daily maintenance OCS for the pa ≥12 weeks □	
Program Financial Criteria: I acknowledge that patient do not have any financial coverage that can fully cover for medication cost e.g. medifund, insurance, employee healthcare benefits (CSC) \Box		
I acknowledge that 1 adult patient has been given 1 FOC Fasenra dose based on the above selection criteria $\;\Box$		
Physician's Name: Clinic/Hospital Name:		Patient's Initial: Identification Number (Last 4 alphanumeric):
•	an's Signature I acknowledgement to be filled b	Date (DD/MM/YYYY) by Asthma and Allergy Association (AAA) Singapore
Clinic/Doctor Name: Serial Number:		AAA Representative:

An initiative supported by AstraZeneca Singapore & Asthma and Allergy Association (AAA) Singapore